These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2559 related articles for article (PubMed ID: 28057034)

  • 61. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
    Novello S; Vavalà T; Levra MG; Solitro F; Pelosi E; Veltri A; Scagliotti GV
    Clin Lung Cancer; 2013 May; 14(3):230-7. PubMed ID: 23276821
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience.
    Genestreti G; Burgio MA; Matteucci F; Piciucchi S; Scarpi E; Monti M; Bucchi L; Parisi E; Crociani L; Gurioli C; Poletti V; Gavelli G
    Technol Cancer Res Treat; 2015 Dec; 14(6):721-7. PubMed ID: 24945370
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.
    Abelson JA; Murphy JD; Trakul N; Bazan JG; Maxim PG; Graves EE; Quon A; Le QT; Diehn M; Loo BW
    Lung Cancer; 2012 Dec; 78(3):219-24. PubMed ID: 23009727
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.
    Wong KH; Panek R; Welsh L; Mcquaid D; Dunlop A; Riddell A; Murray I; Du Y; Chua S; Koh DM; Bhide S; Nutting C; Oyen WJ; Harrington K; Newbold KL
    J Nucl Med; 2016 Dec; 57(12):1843-1850. PubMed ID: 27417648
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
    Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
    Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
    Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery.
    Kim SH; Lee JH; Lee GJ; Jeong S; Kwak YK; Kim HK; Cho DG; Park YH; Yu M; Yoon SC
    Medicine (Baltimore); 2015 Jun; 94(24):e955. PubMed ID: 26091460
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intratumor Textural Heterogeneity on Pretreatment (18)F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer.
    Oh JS; Kang BC; Roh JL; Kim JS; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Aug; 22(8):2746-54. PubMed ID: 25487968
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Use of
    Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
    [No Abstract]   [Full Text] [Related]  

  • 76. Primary tumor standardized uptake value (SUVmax) measured on
    Hui Z; Wei F; Ren H; Xu W; Ren X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Use of Diffusion-Weighted Imaging and
    Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
    Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer.
    Kozak MM; Murphy JD; Schipper ML; Donington JS; Zhou L; Whyte RI; Shrager JB; Hoang CD; Bazan J; Maxim PG; Graves EE; Diehn M; Hara WY; Quon A; Le QT; Wakelee HA; Loo BW
    J Thorac Oncol; 2011 May; 6(5):920-6. PubMed ID: 21774104
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
    Hellwig D; Graeter TP; Ukena D; Georg T; Kirsch CM; Schäfers HJ
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):892-9. PubMed ID: 15573074
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
    Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 128.